Checkpoint Therapeutics Inc (NASDAQ: CKPT) on Tuesday, soared 0.25% from the previous trading day, before settling in for the closing price of $4.01. Within the past 52 weeks, CKPT’s price has moved between $1.38 and $4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -49.45% annually for the last half of the decade. The company achieved an average annual earnings per share of 82.04%. With a float of $62.05 million, this company’s outstanding shares have now reached $83.76 million.
In an organization with 24 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -31551.22%, operating margin of -137009.76%, and the pretax margin is -137170.73%.
Checkpoint Therapeutics Inc (CKPT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Checkpoint Therapeutics Inc is 25.93%, while institutional ownership is 24.07%. The most recent insider transaction that took place on Apr 02 ’25, was worth 60,964. In this transaction CEO, President and Director of this company sold 15,090 shares at a rate of $4.04, taking the stock ownership to the 3,759,929 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Chief Financial Officer sold 12,322 for $4.05, making the entire transaction worth $49,904. This insider now owns 1,446,322 shares in total.
Checkpoint Therapeutics Inc (CKPT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 82.04% per share during the next fiscal year.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Trading Performance Indicators
Checkpoint Therapeutics Inc (CKPT) is currently performing well based on its current performance indicators. A quick ratio of 0.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8418.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.27, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach 1.13 in one year’s time.
Technical Analysis of Checkpoint Therapeutics Inc (CKPT)
Let’s dig in a bit further. During the last 5-days, its volume was 2.11 million. That was inferior than the volume of 2.42 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 59.34%. Additionally, its Average True Range was 0.08.
During the past 100 days, Checkpoint Therapeutics Inc’s (CKPT) raw stochastic average was set at 77.52%, which indicates a significant increase from 66.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 8.68% in the past 14 days, which was lower than the 101.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.57, while its 200-day Moving Average is $3.05. However, in the short run, Checkpoint Therapeutics Inc’s stock first resistance to watch stands at $4.04. Second resistance stands at $4.05. The third major resistance level sits at $4.07. If the price goes on to break the first support level at $4.01, it is likely to go to the next support level at $3.99. Assuming the price breaks the second support level, the third support level stands at $3.98.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Key Stats
Market capitalization of the company is 336.73 million based on 83,764K outstanding shares. Right now, sales total 40 K and income totals -56,240 K. The company made 0 K in profit during its latest quarter, and -9,730 K in sales during its previous quarter.
